# B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

> **NCT05150522** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen University General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** BCMA CAR-T cells

## Key facts

- **NCT ID:** NCT05150522
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2024-07
- **Final completion:** 2024-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150522, "B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05150522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*